Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04014452
Other study ID # PekingUTHweiyuanRCT
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 15, 2019
Est. completion date November 1, 2020

Study information

Verified date June 2020
Source Peking University Third Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Complicated pregnancies refer some special complications, including twin to twin transfusion syndrome(TTTS), twin reverse arterial perfusion(TRAP), selective intrauterine fetal growth restriction(sIUGR), twin anemia-polycythemia sequence(TAPS), one fetal death or structural abnormalities, etc. Complicated twins are often associated with high perinatal morbidity and mortality. Severe complicated twins can be treated with fetal-reduction surgery during pregnancy, which can improve the survival rate of retained fetuses and reduce the disability rate. The managements include mechanical umbilical cord ligation or thermal coagulation obliteration, such as bipolar coagulation (BCC), radiofrequency ablation (RFA), and laser coagulation.Nowadays radiofrequency ablation reduction is the most common, which processes a higher survival rate and fewer maternal and fetal complications compared with other ways.Latest experience suggests that microwave ablation(MWA) is also easy to be used and the therapeutic effect is similar with RFA, but there is no convincing evidence. Compared with radiofrequency ablation, MWA has the advantages of simple operation and time, and avoids the problems of tissue carbonization, drying and heat sink effect. For fetation reduction surgery, the main advantage is that the endothermic effect near the blood vessels is smaller, which enables microwave fetation reduction to have a larger ablation range and a higher thermal effect. This study is comparing Microwave Ablation(MWA) and radiofrequency ablation (RFA) methods for selective fetal reduction in the treatment of complicated monochorionic (MC) multifetal gestations.

This is a pilot randomised controlled trial(RCT) of 60 patients who undergo selective fetal reduction. The subjects of this study were all pregnant women and their offspring who underwent reduction surgery in the third hospital of Beijing University, and patients are randomly assigned 1:1 to different intervention groups by parallel design. The outcome evaluators were blind. Collecting their surgery, clinical information and maternal and fetal complications at a week and a month after surgery, 42 days and 6 months after delivery, to verify the safety and efficacy of MWA, and find a better treatment plan for complicated monochorionic pregnancies .The primary outcome was neonatal survival rate.


Description:

Medical charts were reviewed for the details of surgery and the pregnancy outcomes if the patient delivered at the authors'institution. In the event of delivery at distant locations, patients were contacted by telephone to obtain delivery and neonatal information. Patients are randomly assigned 1:1 to different intervention groups by parallel design. Chorionicity was assessed by the referring physicians during the first trimester. All patients underwent comprehensive ultrasound examination to confirm the fetal diagnosis, chorionicity, amnionicity and cervical length upon arrival at Peking University Third Hospital. Monochorionicity was confirmed through the ultrasound findings of a single placenta, a thin intervening membrane, lack of a lambda sign and concordance for fetal gender. Patients were counseled about the risks and benefits of expectant management vs. selective reduction. Written informed consent was obtained. Statistical analysis was performed using the statistical software Statistical Product and Service Solutions(SPSS), for comparison of entry and outcome variables using the chi-square test, Fisher's exact test and the Student's t-test, where appropriate. P < 0.05 was considered as statistically significant.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date November 1, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

1. Complicated monochorionic pregnancies women;

2. Having the indication of selective reduction;(TTTS III or IV, TRAP, severe sIUGR, Twin malformation inconsistency or stillbirth,three or more fetuses with monochorionic pregnancies requiring reducing the number of fetuses)

3. The reduction surgery should be done after 15 weeks of gestation;

4. Willingness to participate in the trial and having provided written consent.

Exclusion Criteria:

1. Preoperative examination shows that patient is not appropriate to undergoing reduction surgery, such as acute infection of the organ system, especially the urinary system.

2. Patients need to perform acute reduction surgery due to the progress of the disease and the surgery cannot be scheduled.

3. Other diseases that may affect the experimental results: neuropsychiatric diseases and congenital diseases.

Study Design


Intervention

Procedure:
Microwave ablation
Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
Radiofrequency ablation
Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.

Locations

Country Name City State
China Peking University Third Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University Third Hospital Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neonatal survival rate The proportion of live births at 28 days postpartum a month after delivery
Secondary Surgical injury to fetal Using MRI to assess postoperative thermal injury and nerve injury of fetus at 28 weeks gestation
Secondary Postoperative complications Frequency of PPROM, premature delivery, frequency of infection, procedure-to-delivery interval, <28 weeks of intrauterine fetal death/abortion, >28 weeks of intrauterine fetal deat and <32 weeks premature delivery at delivery
Secondary Perinatal outcomes Using Apgar Score to assess neonatal asphyxia(Heart rate, respiration, muscle tone, laryngeal reflex and skin color within one minute after birth are taken as the basis, each item is 0~2 points, the full mark is 10 points. 8~10 belong to normal newborns. 4~7 can be classified as mild asphyxiation, 0~3 as severe asphyxiation) a week after delivery
Secondary Growth of the children The height of the surviving fetus at 6 months 6 months postpartum
See also
  Status Clinical Trial Phase
Recruiting NCT04626986 - Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor N/A
Completed NCT05068076 - Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC N/A
Not yet recruiting NCT03490890 - Microwave Ablation in Ground Glass Nodules Phase 2
Completed NCT06031129 - Butorphanol in Pain Following Ablation for Hepatic Tumor N/A
Recruiting NCT03082378 - Central Obesity and Hepatocellular Carcinoma N/A
Recruiting NCT03609268 - Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma N/A
Recruiting NCT03963726 - Clinical Efficacy of Stereotactic Radiotherapy and Microwave Ablation for Liver Metastases From Colorectal Cancer. N/A
Recruiting NCT05361538 - Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm N/A
Recruiting NCT05444478 - Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma N/A
Recruiting NCT05990257 - CMRA for US-guided-MWA of Liver Tumors N/A
Recruiting NCT03286413 - Comparison of Microwave Ablation With Cryoablation for Breast Tumor N/A
Recruiting NCT03277716 - Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge N/A
Terminated NCT04803890 - "No-Touch" Radiofrequency Ablation for Small Hepatocellular Carcinoma (≤ 3cm): A Prospective Multicenter Study N/A